What did Jefferies do in the March 12, 2026 BMRN analyst rating update?

Jefferies reiterated a Buy on BioMarin on March 12, 2026 and called data viable. The firm did not publish a new price target. The note confirms existing confidence without raising expectations.

How should investors interpret a maintained Buy in the BMRN analyst rating?

A maintained Buy signals continued analyst confidence but not a fresh upgrade. It suggests support for long-term thesis while keeping short-term volatility possible. Investors should weigh pipeline risk and upcoming catalysts.

Did the Jefferies note include a BMRN price target?

No. The Jefferies note on March 12, 2026 did not list a new BMRN price target. Absence of a target means the firm reaffirmed its view without changing valuation guidance.

How does the BMRN analyst rating affect trading and risk?

Analyst reiterations can stabilize sentiment but do not remove clinical risk. For traders, the maintained Buy may reduce downside conviction. For long-term investors, it supports holding while monitoring trial and regulatory milestones.

Analyst Ratings

Jefferies Maintains Buy on BioMarin Pharmaceutical Inc. (BMRN) March 2026

ByDanny Kontos March 13, 2026March 13, 2026

BMRN analyst rating: Jefferies reiterated a Buy on BioMarin Pharmaceutical Inc. on March 12, 2026. The firm described trial data as “viable and a positive sign.” StreetInsider published the note and the stock was down 1.6% ($-0.96) on the news. Meyka AI’s platform flagged this as a confirmation of prior Buy-oriented coverage for BMRN. The update keeps investors focused on BioMarin’s pipeline catalysts and clinical readouts.